Navigation Links
Celladon Announces Presentation of Clinical Data From First-in-Human MYDICAR(R) Trial for Advanced Heart Failure at American Heart Association Scientific Sessions
Date:11/9/2008

Phase 1 Data Demonstrate Safety and Improvement in Heart Failure in a

Majority of Patients

NEW ORLEANS, Nov. 9 /PRNewswire/ -- Celladon Corporation announced today results from the first nine patients treated with MYDICAR(R), a genetically-targeted enzyme replacement therapy for advanced heart failure, showing the product was safe and demonstrating improvement across a number of key parameters. Phase 1 data from the "Calcium Up-Regulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID Trial), a First-in-Human Phase 1/2 Clinical Trial" were presented at the American Heart Association Scientific Sessions 2008.

This first phase of the multi-center trial was designed to investigate safety and biological effects of restoring SERCA2a enzyme activity in heart muscle cells. The enzyme levels are decreased in late stages of heart failure, and extensive research shows loss of SERCA2a levels represents a common pathway resulting in a defect in the ability of the heart to contract properly. Replacing the enzyme may restore function and reverse heart failure.

"The CUPID trial is the first to attempt to rescue a failing heart by replacing an enzyme known to play a critical role in normal cardiac muscle cell activity," said Brian E. Jaski, M.D., Medical Director of Advanced Heart Failure, Sharp Memorial Hospital, San Diego Cardiac Center, San Diego, and a principal investigator on the study. "Our objective in this study is not only to improve the symptoms of heart failure, but restore physiologic function and reverse the severity of the disease in this chronic patient population."

Celladon scientists, led by company co-founder Roger J. Hajjar, M.D., Director of the Cardiovascular Research Center at Mount Sinai School of Medicine, New York, developed MYDICAR for restoring the SERCA2a calcium transporter in heart failure and validated the overall beneficial effects on cardiac function. MYDICAR
'/>"/>

SOURCE Celladon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Portola Announces Data Presentations Relevant to Its Lead Phase II Antithrombotic Compounds at American Heart Association Scientific Sessions 2008
2. Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
3. VIA Pharmaceuticals Announces Conference Call and Webcast to Discuss VIA-2291 Phase 2 Data Presentations at AHA
4. NicOx Announces Favorable Blood Pressure Data for Naproxcinod in a Large ABPM Study
5. Michael J. Fox Foundation Announces $11 Million in 2009 Funding for Translational, Pre-Clinical and Clinical Parkinsons Disease Research
6. CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine
7. Mpex Pharmaceuticals Announces Initiation of a Phase 2 Clinical Trial of Aerosol MP-376 in COPD
8. CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma
9. Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
10. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
11. Lutonix Inc. Announces $20 Million Series B Financing

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)...FirstCall/ -- Hologic, Inc. (Hologic or the Compan...urer and supplier of premium diagnostics, medical ... serving the healthcare needs of women, today anno...l year ended September 26, 2009. In addition, Holo...moted Robert Cascella to Chief Executive Officer e...
(Date:11/9/2009)...wswire/ -- Momentum is building for the early Dec...d second P-MEC India pharma ingredients, services ... 600 exhibitors from over 80 countries are exp... events, being held on 1 - 3 December. ,, In a...s include two new launches. BioPh India will foc...
(Date:11/9/2009)...swire-FirstCall/ -- Par Pharmaceutical Companies, ...ended the expiration date and increased the purcha...ch Auction" tender offer, in which Par is offering...e principal amount, or up to approximately 82.7%, ...ertible Notes due 2010. ,, The price for the of...
Breaking Medicine Technology:Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 2Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 3Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 4Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 5Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 6Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 7Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 8Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 9Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 10Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 11Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 12Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 13Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 14Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 15Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 16Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 17Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 18Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 19Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 20Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 21Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 22Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 23Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 24Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 25Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 26Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 27Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 28Forecast Looks Good for India Pharma Shows 2Forecast Looks Good for India Pharma Shows 3Par Pharmaceutical Announces Extension and Increase in Maximum Purchase Price for 'Modified Dutch Auction' Tender Offer to Purchase up to $65,000,000 Aggregate Principal Amount of its Currently Outstanding 2.875% Senior Subordinated Convertible Note 2Par Pharmaceutical Announces Extension and Increase in Maximum Purchase Price for 'Modified Dutch Auction' Tender Offer to Purchase up to $65,000,000 Aggregate Principal Amount of its Currently Outstanding 2.875% Senior Subordinated Convertible Note 3Drinking in Adolescence May Lead to Risky Choices Later 57868 1Drinking in Adolescence May Lead to Risky Choices Later 57868 2Drinking in Adolescence May Lead to Risky Choices Later 57868 3Heritage Provider Network and Dr Richard Merkin Highlight Cutting Health Care Costs Using Electronic Medical Records 57866 1Heritage Provider Network and Dr Richard Merkin Highlight Cutting Health Care Costs Using Electronic Medical Records 57866 2Alzheimers Foundation of America Names Actor Hector Elizondo as Honorary Chairman 57864 1Alzheimers Foundation of America Names Actor Hector Elizondo as Honorary Chairman 57864 2
...rther Validate Significant Anti-Tumor Potential of...pany,s PS-Targeting Platform- , , -Treatment with...Tumor Growth in a Prostate Cancer Model by More th...Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), ...ing monoclonal antibodies for the treatment of can...
...Association for Cancer Research - , , PRINCETON, ...day announced preclinical efficacy and safety data...ovel and potentially important cancer targets (CXC... additional research in the area of antibody-drug ...t the Annual Meeting of the American Association f...
Other Medicine Technology:Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrine's Fully Human Anti-PS Antibody in Prostate Cancer Model 2Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrine's Fully Human Anti-PS Antibody in Prostate Cancer Model 3Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrine's Fully Human Anti-PS Antibody in Prostate Cancer Model 4Medarex Announces Preclinical Data from Multiple Research Programs Demonstrating Anti-Tumor Activity in Cancer 2Medarex Announces Preclinical Data from Multiple Research Programs Demonstrating Anti-Tumor Activity in Cancer 3Medarex Announces Preclinical Data from Multiple Research Programs Demonstrating Anti-Tumor Activity in Cancer 4
(Date:11/9/2009)... Tarkett Sports, the worldwide leader in sports su...t offering with a more complete and innovative ran...r sports flooring experts and the launch of www.t... (PRWEB) November 9, 2009 -- Tarkett Sports, rede...ng products includes hardwood and synthetic basket...
(Date:11/9/2009)...ess Month Highlighted During Broadcast ,, WASH...cer Alliance (LCA) announced that LCA staff, advoc...e New York Stock Exchange(TM) (NYSE) tomorrow afte...com.com/cgi-bin/prnh/20081016/LCALOGO ) ,, Fiv...advocate, Richard Heimler will mark the end of the...
(Date:11/9/2009)... Nov. 9 Sutter Health, a family of...h care service providers, is donating $255,000 to ...f local food banks will share the quarter-million-...he tables of thousands of families across the nort...of partnering with and supporting charitable progr...
(Date:11/9/2009)... President Obama,s promise to not expand abortion ...ishops still concerned for poor, elderly ,, WA...al Francis George of Chicago, president of the Uni...the November 7 decision of the U.S. House of Repre...ey from paying for elective abortions. ,, In a...
(Date:11/9/2009)... enlargement, study finds , , MONDAY, No...actor for left atrial enlargement, which increases..., a new study shows. , Atrial fibrillation is t...art rhythm or heartbeat). , Researchers analyz...Germany who were followed for 10 years. The study ...
Breaking Medicine News(10 mins):Health News:Tarkett Sports Launches Revamped Indoor Sports Flooring Division and New Indoor Website 2Health News:Lung Cancer Alliance Staff and Advocates to Ring Closing Bell of New York Stock Exchange(TM) 2Health News:Sutter Health Donates $255,000 to Help the Hungry This Holiday Season 2Health News:Cardinal George Lauds House Action to Ban Federal Funds for Abortion; Promises Vigilance as Senate Pursues Health Care Reform, Wary About Affect on Poor, Elderly 2Health News:Cardinal George Lauds House Action to Ban Federal Funds for Abortion; Promises Vigilance as Senate Pursues Health Care Reform, Wary About Affect on Poor, Elderly 3
...W YORK, and WINSTON-SALEM, N.C., Oct. 9 Castle,Co...oin forces with,DrScore.com to bring valuable new ...r respective Web sites, http://www.CastleConnolly...hese and other,physicians they have been to as pat...
... COLUMBIA, Mo. Mr. Jones has chronic back pain. ... time because of the pain. He cannot lose weight b...s a case study in a publication by a University of...had side effects that made it difficult for Jones ...
...inic is Sixth Location for Miami Beach Community H...tle Haiti location of,the Miami Beach Community He...he community on Thursday, October 11th from noon t...which,runs a comprehensive network of federally qu...
...07-2008 Southeastern Pennsylvania Flu Shot Guide A...nfo.org, PHILADELPHIA, Oct. 9 PhillyHealthInfo i...shots in Philadelphia, Bucks, Chester,Delaware, an... -- Where to go for free or low cost flu shots. ...
... COLUMBUS, Ohio -- Nurses and physicians at Nation...ology to help young burn victims endure the extrem...d of traditional distraction devices, such as book...n wounds. , Its long been known that the actual...
...RRIMAC, Mass., Oct. 9 Nurse Savvy Research Group .... Nursesavvy.com is an online medical information... with nurse based recommendations as to which,doct...ed through an online survey and written questionna...
Other Medicine News:Health News:Castle Connolly Medical Ltd. Partners with DrScore.com to Provide Additional Quality Information About Doctors to Consumers 2Health News:More than a pill: Complementary medicine can help with chronic pain 2Health News:New Medical Clinic at Center for Haitian Studies to Host Open House on October 11th 2Health News:Virtual game helps children escape realities of burn unit 2Health News:Nursesavvy.com Promoting Quality Healthcare for Everyone 2
Simplex™ P Bone Cement with Tobramycin
Palacos Bone Cement
Occu-Flo Punctum Plugs
UltraPlug Collagen Absorbably Punctal Plugs
Medicine Products: